These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 11674923)
81. Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitis-disturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis. Yamada T; Yamamoto H; Kubo S; Sakashita M; Tokunaga T; Susuki D; Narita N; Ogi K; Kanno M; Yamashita S; Terasawa Y; Kayano Y; Masada M; Fujieda S Allergy Asthma Proc; 2012; 33(2):e9-16. PubMed ID: 22525384 [TBL] [Abstract][Full Text] [Related]
82. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Chervinsky P; Kunjibettu S; Miller DL; Prenner BM; Raphael G; Hall N; Shah T Ann Allergy Asthma Immunol; 2007 Jul; 99(1):69-76. PubMed ID: 17650833 [TBL] [Abstract][Full Text] [Related]
83. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. Simons FE; Prenner BM; Finn A; J Allergy Clin Immunol; 2003 Mar; 111(3):617-22. PubMed ID: 12642846 [TBL] [Abstract][Full Text] [Related]
84. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study. del Cuvillo A; Montoro J; Bartra J; Valero A; Ferrer M; Jauregui I; Dávila I; Sastre J; Mullol J Rhinology; 2010 Jun; 48(2):201-5. PubMed ID: 20502761 [TBL] [Abstract][Full Text] [Related]
86. [Evaluation of the efficiency and safety of the loratadine with pseudoephedrine combination drug in treatment of seasonal allergic rhinitis]. Zawisza E; Lipiec A; Rapiejko P Pol Merkur Lekarski; 1998 Feb; 4(20):66-8. PubMed ID: 9634291 [TBL] [Abstract][Full Text] [Related]
88. Symptomatic treatment of pollen-related allergic rhinoconjunctivitis in children: randomized controlled trial. Wartna JB; Bohnen AM; Elshout G; Pijnenburg MW; Pols DH; Gerth van Wijk RR; Bindels PJ Allergy; 2017 Apr; 72(4):636-644. PubMed ID: 27696447 [TBL] [Abstract][Full Text] [Related]
89. Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. Burtin B; Duchateau J; Pignat JC; Donnelly F; Bousquet J J Investig Allergol Clin Immunol; 2000; 10(2):66-70. PubMed ID: 10879992 [TBL] [Abstract][Full Text] [Related]
90. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Kaszuba SM; Baroody FM; deTineo M; Haney L; Blair C; Naclerio RM Arch Intern Med; 2001 Nov; 161(21):2581-7. PubMed ID: 11718589 [TBL] [Abstract][Full Text] [Related]
91. Single-patient drug trial methodology for allergic rhinitis. Reitberg DP; Del Rio E; Weiss SL; Rebell G; Zaias N Ann Pharmacother; 2002 Sep; 36(9):1366-74. PubMed ID: 12196053 [TBL] [Abstract][Full Text] [Related]
92. [Nasal budesonide plus zafirlukast vs nasal budesonide plus loratadine-pseudoephedrine for controlling the symptoms of rhinitis and asthma]. Benitez HH; Arvizu VM; Gutiérrez DJ; Fogelbach GA; Castellanos Olivares A; Vázquez Nava F; Velázquez HC; González Pérez Mdel C; Mora Nieto A; Rodríguez EC Rev Alerg Mex; 2005; 52(2):90-5. PubMed ID: 16158782 [TBL] [Abstract][Full Text] [Related]
93. Treatment for seasonal allergic rhinitis by Chinese herbal medicine: a randomized placebo controlled trial. Xue CC; Thien FC; Zhang JJ; Da Costa C; Li CG Altern Ther Health Med; 2003; 9(5):80-7. PubMed ID: 14526714 [TBL] [Abstract][Full Text] [Related]
94. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Crampton HJ Clin Ther; 2002 Nov; 24(11):1800-8. PubMed ID: 12501875 [TBL] [Abstract][Full Text] [Related]
95. Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients--an observational, cross sectional study in four countries in Europe. Virchow JC; Kay S; Demoly P; Mullol J; Canonica W; Higgins V J Med Econ; 2011; 14(3):305-14. PubMed ID: 21488807 [TBL] [Abstract][Full Text] [Related]
96. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Juniper EF; Guyatt GH Clin Exp Allergy; 1991 Jan; 21(1):77-83. PubMed ID: 2021881 [TBL] [Abstract][Full Text] [Related]
97. Impact of allergic rhinitis symptoms on quality of life in primary care. Bousquet PJ; Demoly P; Devillier P; Mesbah K; Bousquet J Int Arch Allergy Immunol; 2013; 160(4):393-400. PubMed ID: 23183377 [TBL] [Abstract][Full Text] [Related]
98. Influence in the quality of life of the respiratory patients by environmental control and the acaricide Frontac®. Malet A; Cisteró-Bahima A; Amat P; Lluch-Pérez M; Enrique-Miranda E; Alonso R; San Miguel M; Pueyo Mf MG Allergol Immunopathol (Madr); 2002; 30(2):85-93. PubMed ID: 11958740 [TBL] [Abstract][Full Text] [Related]
99. Improvement in Psychological Condition of Patients With Persistent Moderate-Severe Allergic Rhinitis by Drug Therapy Combined With Psychological Intervention. Wang LX; Yang ZC; Kang ZP; Di LL; Tan Y; Peng XB; Liu J Ear Nose Throat J; 2021 Sep; 100(5_suppl):684S-690S. PubMed ID: 32050792 [TBL] [Abstract][Full Text] [Related]
100. Translation into Portuguese and validation of the Rhinitis Control Assessment Test (RCAT) questionnaire. Fernandes PH; Matsumoto F; Solé D; Wandalsen GF Braz J Otorhinolaryngol; 2016; 82(6):674-679. PubMed ID: 27117891 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]